Updates in Targeted Therapies for ALK+ and ROS1+ NSCLC from ESMO 2024 - Episode 8
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.